ImmunoMark London's Biomarkers & Companion Diagnostics stream gathers the pharma and biotech teams who choose assays, platforms and lab partners. Put your team in front of them.
Sponsor London 2027
Our sponsorship team replies within one working day.
Trusted by sponsors from our London 2026 launch edition

If you sell assays, multiplex or proteomics platforms, NGS workflows or specialist biomarker lab services, ImmunoMark Summit is the biomarker conference London pharma and biotech teams use to find partners for their oncology programmes.
The 2nd annual UK edition runs on 3–4 March 2027 with a target of 400+ delegates and two parallel streams. Stream 2, Biomarkers & Companion Diagnostics, is where your buyers spend their two days. The prospectus lists the profiles you would expect a biomarker vendor to chase: Heads and Directors of Translational Medicine, Biomarker Operations Leads, Principal Scientists, VPs of Translational Strategy, and teams in Biomarker Discovery & Development, Bioinformatics / Data Science and Companion Diagnostics.
Companies taking part in 2026 included GSK, Roche, Merck, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb and Incyte, alongside UK biotechs such as ValiRx and Leucid Bio. The 2026 Stream 2 speaker line-up also featured platform and lab-services companies, including Seer, Hologic Diagenode, CellCarta and HAWK Biosystems, so a vendor voice on stage is normal here rather than an exception.
By sector, 55–60% of delegates come from biotech and pharma and 10–15% from academia. By seniority, 45–50% are senior leaders (executives, directors, heads) and 20–30% are scientists, PIs and technologists: the people who sign off a platform and the people who will run it.
Different roles judge a biomarker platform on different things. This table maps the main Stream 2 buyer roles to what they evaluate and the London 2027 session where that topic is on stage.
| Buyer role | What they are evaluating | Related London 2027 session |
|---|---|---|
| Head / Director of Translational Medicine | Whether a platform can carry a candidate biomarker from discovery data into a clinical-trial assay | Day 1 · The Future of Biomarker-Driven Oncology |
| Biomarker Operations Lead | Turnaround, sample logistics, lab capacity and assay transfer between sites | Day 2 · Multiplex & Programmable Biomarker Platforms |
| Principal Scientist, biomarker discovery | Proteomic and multiplex depth, panel flexibility, sample input requirements | Day 1 · Leveraging Space Genomics to Discover Novel Biomarkers and Identify Emerging Therapeutic Strategies |
| Biomarker data analytics and bioinformatics leads | Data formats, pipelines and how platform output feeds their analysis | Day 2 · Real-World Evidence Integration into Biomarker Strategy |
| Medical diagnostics and CDx leads | Whether an assay can be validated for clinical use and support a diagnostic claim | Day 1 · Keynote: Clinical Utility of Biomarkers (AstraZeneca) |
| Pathology and molecular diagnostics clinicians | Tissue requirements and fit with routine pathology workflows | Day 1 · Digital Pathology & Spatial Transcriptomics in Oncology |
The 2027 Stream 2 speaker panel includes Matteo Cesaroni, Head of Biomarker Data Analytics at Sanofi, Nitya Nair, Group Head, Translational Biomarker Strategy at Roche, and Espen Walker, Head of Global Medical Diagnostics at AstraZeneca. Expect their peers in the audience to bring the same questions.
Booth traffic is a bonus. For a platform vendor, the pre-scheduled 1:1 programme is the main route to a technical buyer with a live project.
At London 2026, sponsors averaged 15–25 meetings each and more than 200 meetings took place across the event.
Most platform companies at a biomarker summit in London need meetings first and stage time second. These three packages cover that range.
Choose Stream 2 and you get a 30-minute talk on Day 1, the same day as the AstraZeneca and Roche diagnostics sessions, plus a meeting programme large enough to cover several pharma accounts.
For lab-services and assay teams who sell through technical conversations rather than a stand. Pick the volume that matches your sales team.
For instrument and kit companies who need a visible stand for demos across both days, and will work the floor rather than a fixed diary.
Gold (6 meetings, 30-minute Day 2 pre-lunch talk) and Silver (15-minute Day 2 post-lunch talk, no pre-scheduled meetings) are also available in Stream 2. Full details are on the London sponsorship opportunities page, and the ROI calculator below lets you test each package against your deal size.
Stream 2 sponsor slots are fixed in the agenda: the Platinum slots run through Day 1, Gold slots sit in the Day 2 morning and the Silver slot opens the Day 2 afternoon. Each package lets you choose your stream, so the earlier you commit, the more choice you have over where your talk lands.
If your platform is aimed at the discovery end of oncology work, such as spatial, single-cell or AI discovery, see our page on the oncology biomarker conference in London for discovery tools. If you build or run assays for companion diagnostics, the companion diagnostics conference London page covers the CDx partnering angle. For a technology-by-technology view across editions, see liquid biopsy, spatial and multiplex platforms at ImmunoMark.
Whether you call it a biomarker congress London teams plan around or a focused two-day summit, the test is the same: the right buyers, booked into your diary.
Tell us your platform and target accounts, and we will suggest the Stream 2 package that fits.
Request the prospectusPick a package, add your own numbers and see the pipeline it creates. London 2026 sponsors averaged 15 to 25 meetings each, with 70% senior decision-makers in the room.
1. Choose a package
2. Your numbers
Year-one value of a new pharma or biotech customer
Booth visits, networking and questions after your talk
Share of conversations worth a proposal
Your typical close rate
Sponsorship plus travel and team costs
expected first-year revenue for every £1 of your event budget
Estimates only, based on the numbers you enter. Meetings and inclusions from the London 2027 sponsorship prospectus. 1:1 meetings are pre-scheduled with delegates you choose from the attendee list.
What sponsors said
Here is what sponsors told us at our London 2026 launch edition.
We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Most assay, proteomics, multiplex and NGS vendors choose Stream 2, Biomarkers & Companion Diagnostics, because it covers biomarker discovery, validation, digital pathology, multiplex platforms and CDx. Platinum, Gold and Silver all let you choose your stream. If your platform also serves immune-monitoring work in IO trials, Stream 1 (Next-Gen Immuno-Oncology) is an option.
Ten days before the event you receive the full delegate list with profiles and choose who you want to meet. The meetings are pre-arranged 20-minute slots. The wishlist feature lets you flag the people and companies you want to reach. Platinum includes 10 meetings, Gold 6 and Headline 15, and the Exclusive 1:1 Meetings package offers 3, 5, 7 or 10.
Yes. The Exhibitor package gives you a 10 x 6 ft booth, 2 team passes plus 2 client passes, the delegate list with contact details, the wishlist feature and your logo on the website and in the brochure. It does not include pre-scheduled meetings. If booked meetings matter more than a stand, the Exclusive 1:1 Meetings package is built for that.
London 2026 (5–6 March 2026) had 300+ attendees from 100+ companies, 70% of them senior decision-makers. More than 200 meetings were conducted, sponsors averaged 15–25 meetings each, and title sponsors received 55+ pre-scheduled 1:1 meetings.
Passes depend on the package: Headline includes 10 delegate and 10 client passes, Platinum 8 + 8, Gold 6 + 6, Silver 4 + 4 and Exhibitor 2 + 2. The Exclusive 1:1 Meetings package includes 2–4 passes plus drinks reception passes, and each branding package includes 2 passes.
Tell us who you want to meet. We will send the prospectus, current package availability and a recommendation within one working day.